Schizophrenia Dominates Psychiatric Drug Deal-Making Since 2008
Of 34 deals in the psychiatric disorder space since 2008, none have been mergers and acquisitions, but two-thirds of such transactions have involved licensing of compounds before regulatory approval. The major deals in the space have been a multi-compound collaboration between Otsuka and Lundbeck and the failed tie-up between AstraZeneca and Targacept.
You may also be interested in...
Between 2010 and the first quarter of 2013, biopharma engaged in 70 deals involving neurodegenerative disease assets covering a wide variety of targets – possibly a consequence of uncertainty about the underlying pathophysiology. AstraZeneca was the top deal maker in the field even as it moved away from CNS as a core therapeutic area.
Two firms will collaborate on the development and marketing of new psychiatric products, including an intramuscular depot formulation of the blockbuster antipsychotic medicineLundbeck Inc. , Abilify.
The US FDA and NIST have agreed to help industry modernize and update pharmaceutical manufacturing methods and to improve supply chain resilience.